Clinical Trials Browser

Neurofibromatosis 1, Neurofibroma, Plexiform

Neurofibromatosis 1, Neurofibroma, Plexiform

Triple Negative Breast Neoplasms

Neurofibromatosis 1, Sarcoma, Neurofibrosarcoma

Carcinoma, Non-Small-Cell Lung

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Primary Myelofibrosis

Gallbladder Neoplasms, Recurrence

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Breast Neoplasms

Neurofibromatosis 1, Neurofibrosarcoma

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

Ependymoma, Glioma, Meningioma, Neuroma, Acoustic, Neurofibromatosis 2

Breast Neoplasms

Neurofibromatosis 1, Neurofibroma, Plexiform

Neurofibromatosis 1

Neurofibromatosis 1

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

Non-small Cell Lung Cancer Metastatic

Neurofibromatosis 1, Neurofibrosarcoma

Uveal Melanoma, Melanoma

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Rectal Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Carcinoma, Non-Small-Cell Lung, Neoplasms

Breast Neoplasms

Triple Negative Breast Neoplasms

Breast Neoplasms

AIDS-related Kaposi sarcoma, Acquired Immunodeficiency Syndrome, Sarcoma, Kaposi

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Neoplasm Metastasis, Thyroid Diseases, Thyroid Neoplasms

Breast Neoplasms

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

Triple Negative Breast Neoplasms

Carcinoma, Hepatocellular, Liver Neoplasms

Clinical Trials

NF114

NF113

AMTEC IIT: Phase 2 Multiarm Study in TNBC

Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas

A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

ESMART

Selumetinib and Azacitidine in High Risk Chronic Blood Cancers

A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer

Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer

Selumetinib and Olaparib in Solid Tumors

MEKMDM2

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

SEL-TH-1601

SAFIR02_Breast

LS-NF1PNs

Clinical Study on the Treatment of Type I Neurofibromatosis With Smeitinib Hydrosulfate Capsule

The Clinical Study of the Treatment of Patients With Type I Neurofibromatosis With Smetinib Hydrosulfate Capsule

DOC-MEK

Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer

SAFIR02_Lung

SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors

Intermittent Selumetinib for Uveal Melanoma

SeluDex

DREAMtherapy

Selumetinib and Paclitaxel as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

MEKRT

BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

A Phase I Trial of Vandetanib (AZD6474) and Selumetinib (AZD6244) for Solid Tumours Including Non Small Cell Lung Cancer (VanSel-1)

Personalized Treatment Selection for Metastatic Breast Cancer

TORCMEK

Fulvestrant With or Without AZD6244 in Treating Patients With Advanced Breast Cancer That Progressed After Aromatase Inhibitor Therapy

SCART

Selumetinib in Combination With Gefitinib in NSCLC Patients

MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)

Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244

Evaluation of the Use of AZD6244 to Induce Increased ER Expression and Anti-Estrogen Response in ER-Negative/Low Breast Cancer

ABC-04

Neoadjuvant Chemotherapy Docetaxel With or Without SELUMETINIB in Patients With Triple Negative Breast Cancer

AZD6244 and Sorafenib in Advanced Hepatocellular Carcinoma